These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16914902)

  • 1. Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
    Yamazaki T; Sawada U; Kura Y; Ito T; Takeuchi J; Hatta Y; Aikawa S; Takei K; Ishizuka H; Saiki M; Uenogawa K
    Acta Haematol; 2006; 116(2):90-5. PubMed ID: 16914902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
    Miyazaki K; Masuya M; Yamaguchi M; Isaka S; Nakase K; Kobayashi T; Nakamura S; Shiku H
    Rinsho Ketsueki; 2005 Sep; 46(9):1065-70. PubMed ID: 16440766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
    Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
    Motomura S; Hashimoto C; Kodama F; Maruta A; Sakai R; Fujita H; Tomita N; Fujisawa S; Harano H; Koharazawa H; Fujimaki K; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2005 May; 46(5):350-7. PubMed ID: 16444968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S
    Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.
    Kouzaki H; Kitanishi T; Kitano H; Suzuki M
    Auris Nasus Larynx; 2004 Mar; 31(1):79-83. PubMed ID: 15041059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
    Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
    Takamatsu Y; Suzumiya J; Utsunomiya A; Maeda K; Matsuoka H; Suzushima H; Tsukada J; Shibata K; Tamura K;
    Eur J Haematol; 2010 May; 84(5):391-7. PubMed ID: 20059527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
    Smith SD; Bolwell BJ; Rybicki LA; Brown S; Dean R; Kalaycio M; Sobecks R; Andresen S; Hsi ED; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2007 Aug; 40(3):239-43. PubMed ID: 17530000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
    Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
    Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
    Takasaki H; Hashimoto C; Takemura S; Motomura S; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Jan; 51(1):57-62. PubMed ID: 20134141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.